Crescent Biopharma, Inc.
CBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001253689
In the last 90 days, Crescent Biopharma, Inc. insiders filed 1 open-market purchase and 7 sales; 82 institutions reported holding it in 13F filings for Q2 2026, worth $532.6M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Crescent Biopharma, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $12.4M in total
- Open-market sells
- 7 filings
- 7 insiders, $285.5K in total
- Insiders trading
- 8
- Net value
- +$12.1M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Crescent Biopharma, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Lynch Ryan | See Remarks | 13,631 | Sep 18, 2026 | 3 |
| Pinkas Jan | Chief Scientific Officer | 21,581 | Sep 18, 2026 | 3 |
| Im Ellie Eunkyung | Chief Medical Officer | 21,446 | Sep 18, 2026 | 3 |
| Scalzo Richard William | Chief Financial Officer | 19,730 | Sep 18, 2026 | 3 |
| Bispham Barbara Harlin | See Remarks | 18,710 | Sep 18, 2026 | 3 |
| Brumm Joshua T | Chief Executive Officer | 271,765 | Sep 18, 2026 | 4 |
| McNeill Jonathan | President and COO | 134,588 | Sep 18, 2026 | 4 |
| Harwin Peter Evan | Director, 10% Owner | 3,601,316Indirect | Jul 20, 2026 | 3 |
| Fairmount Healthcare Fund II L.P. | Director, 10% Owner | 3,601,316Indirect | Jul 20, 2026 | 3 |
| Fairmount Funds Management LLC | Director, 10% Owner | 3,601,316Indirect | Jul 20, 2026 | 3 |
| Kiselak Tomas | Director, 10% Owner | 3,601,316Indirect | Jul 20, 2026 | 3 |
| Lubner David Charles | Director | – | Jun 3, 2026 | 1 |
| Violin Jonathan | Director | – | Jun 3, 2026 | 1 |
| Moran Susan | Director | – | Jun 3, 2026 | 1 |
| Balcom Alexandra | Director | – | Jun 3, 2026 | 1 |
| Doughty Christopher Grant | Chief Business Officer | 62,194 | Dec 17, 2025 | 1 |
| Biotechnology Value Fund L P | 10% Owner | 62,383 | Jun 17, 2025 | 0 |
| BVF Partners L P | 10% Owner | 62,383 | Jun 17, 2025 | 0 |
| BVF Inc | 10% Owner | 62,383 | Jun 17, 2025 | 0 |
| Biotechnology Value Fund II LP | Other: See Explanation of Responses | 62,383 | Jun 17, 2025 | 0 |
| Lampert Mark N | 10% Owner | 62,383 | Jun 17, 2025 | 0 |
| Biotechnology Value Trading Fund OS LP | Other: See Explanation of Responses | 62,383 | Jun 17, 2025 | 0 |
| BVF Partners OS Ltd. | Other: See Explanation of Responses | 62,383 | Jun 17, 2025 | 0 |
| BVF I GP LLC | 10% Owner | 62,383 | Jun 17, 2025 | 0 |
| BVF II GP LLC | Other: See Explanation of Responses | 62,383 | Jun 17, 2025 | 0 |
| BVF GP Holdings LLC | 10% Owner | 62,383 | Jun 17, 2025 | 0 |
| Debbane Raymond | 10% Owner | 6,317,565 | Aug 9, 2024 | 0 |
| Invus Public Equities Advisors, LLC | 10% Owner | 6,317,565 | Aug 9, 2024 | 0 |
| Invus Public Equities, L.P. | 10% Owner | 6,317,565 | Aug 9, 2024 | 0 |
| Siren, L.L.C. | 10% Owner | 6,317,565 | Aug 9, 2024 | 0 |
| Invus Global Management, LLC | 10% Owner | 6,317,565 | Aug 9, 2024 | 0 |
| Rock Edwin | Chief Medical Officer | 680,403 | Jun 24, 2024 | 0 |
| Hahn Brian M. | SVP Finance, CFO | 70,643 | Jun 20, 2024 | 0 |
| Junius Daniel M | Director | 98,459 | May 1, 2024 | 0 |
| Andrews Patricia S | Director | 58,608 | May 1, 2024 | 0 |
| Pearson Timothy R | Director | 24,650 | May 1, 2024 | 0 |
| Goldberg Mark Alan | Director | 24,828 | May 1, 2024 | 0 |
| Jackson Scott Thomas | Director | – | May 1, 2024 | 0 |
| Koenig Scott | Director | 36,750 | May 1, 2024 | 0 |
| King Rachel K. | Director | 515,194 | May 1, 2024 | 0 |
| Semerjian Harout | Chief Executive Officer | 25,000 | Jan 17, 2024 | 0 |
| Rath Chinmaya | SVP and Chief Business Officer | – | Jan 17, 2024 | 0 |
| Johnson Bruce S | SVP & Chief Commercial Officer | 138,980 | Jan 17, 2024 | 0 |
| Artal Group S.A. | 10% Owner | 8,589,064 | Feb 28, 2023 | 0 |
| Artal International S.C.A. | 10% Owner | 8,589,064 | Feb 28, 2023 | 0 |
| Westend S.A. | 10% Owner | 8,589,064 | Feb 28, 2023 | 0 |
| Stichting Administratiekantoor Westend | 10% Owner | 8,589,064 | Feb 28, 2023 | 0 |
| Artal International Management S.A. | 10% Owner | 8,589,064 | Feb 28, 2023 | 0 |
| Wittouck Amaury | 10% Owner | 8,589,064 | Feb 28, 2023 | 0 |
| Sandell Scott D | 10% Owner | 2,237,196Indirect | Jan 27, 2023 | 0 |
Showing the 50 most recent filers.
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 2026 (view filing)4:03 PM ET | Sep 16 | 2 days | Lynch RyanSee Remarks | SSale | −240 | $17.90 | −$4.30K | −1.7%13.6K after | 10b5-1 |
| Sep 18, 2026 (view filing)4:03 PM ET | Sep 16 | 2 days | Pinkas JanChief Scientific Officer | SSale | −658 | $17.90 | −$11.8K | −3.0%21.6K after | 10b5-1 |
| Sep 18, 2026 (view filing)4:02 PM ET | Sep 16 | 2 days | Im Ellie EunkyungChief Medical Officer | SSale | −623 | $17.90 | −$11.2K | −2.8%21.4K after | 10b5-1 |
| Sep 18, 2026 (view filing)4:02 PM ET | Sep 16 | 2 days | Scalzo Richard WilliamChief Financial Officer | SSale | −568 | $17.90 | −$10.2K | −2.8%19.7K after | 10b5-1 |
| Sep 18, 2026 (view filing)4:02 PM ET | Sep 16 | 2 days | Bispham Barbara HarlinSee Remarks | SSale | −620 | $17.90 | −$11.1K | −3.2%18.7K after | 10b5-1 |
| Sep 18, 2026 (view filing)4:02 PM ET | Sep 16-18 | 2 days | Brumm Joshua TChief Executive Officer | SSale | −9.45K | $16.91 | −$159.8K | −3.4%271.8K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)4:01 PM ET | Sep 16-18 | 2 days | McNeill JonathanPresident and COO | SSale | −4.57K | $16.90 | −$77.2K | −3.3%134.6K after | 2 lots10b5-1 |
| Jul 20, 2026 (view filing)5:30 PM ET | Jul 16 | 4 days | Harwin Peter Evan and 3 othersDirector, 10% Owner | PPurchase | +853.5K | $14.50 | +$12.4M | +31.1%3.60M after | |
| Jul 20, 2026 (view filing)5:30 PM ET | Jul 16 | 4 days | Harwin Peter Evan and 3 othersDirector, 10% Owner | PPurchase | +525.9K | $14.50 | +$7.62M | –2.29M after | Derivative |
| Jun 23, 2026 (view filing) | Jun 22 | 1 day | Lynch RyanSee Remarks | SSale | −465 | $17.99 | −$8.37K | −3.2%13.9K after | 10b5-1 |
| Jun 23, 2026 (view filing) | Jun 22 | 1 day | Pinkas JanChief Scientific Officer | SSale | −1.29K | $17.99 | −$23.2K | −5.5%22.2K after | 10b5-1 |
| Jun 23, 2026 (view filing) | Jun 22 | 1 day | Scalzo Richard WilliamChief Financial Officer | SSale | −1.11K | $17.99 | −$20.0K | −5.2%20.3K after | 10b5-1 |
| Jun 23, 2026 (view filing) | Jun 22 | 1 day | Bispham Barbara HarlinSee Remarks | SSale | −1.22K | $17.99 | −$21.9K | −5.9%19.3K after | 10b5-1 |
| Jun 23, 2026 (view filing) | Jun 22 | 1 day | Im Ellie EunkyungChief Medical Officer | SSale | −1.22K | $17.99 | −$21.9K | −5.2%22.1K after | 10b5-1 |
| Jun 23, 2026 (view filing) | Jun 22 | 1 day | McNeill JonathanPresident and COO | SSale | −20.5K | $17.99 | −$369.7K | −12.9%139.2K after | 10b5-1 |
| Jun 23, 2026 (view filing) | Jun 22 | 1 day | Brumm Joshua TChief Executive Officer | SSale | −42.3K | $17.99 | −$761.1K | −13.1%281.2K after | 10b5-1 |
| Dec 8, 2025 (view filing)4:30 PM ET | Dec 4 | 4 days | Harwin Peter Evan and 3 othersDirector, 10% Owner | PPurchase | +1.36M | $13.41 | +$18.2M | +98.0%2.75M after | |
| Dec 8, 2025 (view filing)4:30 PM ET | Dec 4 | 4 days | Harwin Peter Evan and 3 othersDirector, 10% Owner | PPurchase | +131.4K | $13.41 | +$1.76M | –1.77M after | Derivative |
| Aug 9, 2024 (view filing)4:30 PM ET | Aug 7-8 | 2 days | Debbane Raymond and 4 others10% Owner | SSale | −322.4K | $0.1899 | −$61.2K | −4.9%6.32M after | 2 lots |
| Aug 7, 2024 (view filing)4:30 PM ET | Aug 5-6 | 2 days | Debbane Raymond and 4 others10% Owner | SSale | −220.3K | $0.187 | −$41.2K | −3.2%6.64M after | 2 lots |
| Aug 5, 2024 (view filing)4:53 PM ET | Aug 1-2 | 4 days | Debbane Raymond and 4 others10% Owner | SSale | −349.8K | $0.2033 | −$71.1K | −4.9%6.86M after | 2 lots |
| Jul 30, 2024 (view filing)5:16 PM ET | Jul 26-30 | 4 days | Debbane Raymond and 4 others10% Owner | SSale | −1.38M | $0.2286 | −$315.3K | −16.1%7.21M after | 3 lots |
| Jun 24, 2024 (view filing)4:29 PM ET | Jun 20-21 | 4 days | Rock EdwinChief Medical Officer | PPurchase | +305.0K | $0.2584 | +$78.8K | +81.2%680.4K after | 2 lots |
| Jun 20, 2024 (view filing)4:15 PM ET | Jun 18 | 2 days | Hahn Brian M.SVP Finance, CFO | PPurchase | +17.5K | $0.2477 | +$4.33K | +32.9%70.6K after | |
| Sep 25, 2023 (view filing) | Sep 21-22 | 4 days | Rock EdwinChief Medical Officer | PPurchase | +65.4K | $1.38 | +$90.3K | +21.1%375.4K after | 2 lots |
| May 18, 2023 (view filing) | May 17 | 1 day | Hahn Brian M.SVP Finance, CFO | SSale | −3.70K | $1.95 | −$7.21K | −6.5%53.1K after | |
| May 11, 2023 (view filing) | May 10 | 1 day | Junius Daniel MDirector | PPurchase | +30.0K | $1.56 | +$46.8K | +47.4%93.3K after | |
| May 9, 2023 (view filing) | May 8 | 1 day | Johnson Bruce SSVP & Chief Commercial Officer | PPurchase | +13.5K | $1.57 | +$21.2K | +10.8%139.0K after | |
| Feb 28, 2023 (view filing)5:33 PM ET | Feb 24 | 4 days | Artal Group S.A. and 7 others10% Owner | PPurchase | +100.0K | $1.70 | +$170.0K | +1.2%8.59M after | |
| Feb 23, 2023 (view filing)6:23 PM ET | Feb 21-23 | 2 days | Artal Group S.A. and 7 others10% Owner | PPurchase | +400.0K | $1.78 | +$712.3K | +4.9%8.49M after | 3 lots |
| Feb 17, 2023 (view filing)5:29 PM ET | Feb 15-17 | 2 days | Artal Group S.A. and 7 others10% Owner | PPurchase | +1.52M | $2.00 | +$3.03M | +23.1%8.09M after | 3 lots |
| Feb 13, 2023 (view filing)5:45 PM ET | Feb 9 | 4 days | Artal Group S.A. and 7 others10% Owner | PPurchase | +11.5K | $3.24 | +$37.1K | +0.2%6.57M after | |
| Jan 27, 2023 (view filing) | Jan 25-26 | 2 days | Sandell Scott D10% Owner | SSale | −3.65M | $3.14 | −$11.5M | −62.0%2.24M after | 4 lots |
| Jan 6, 2023 (view filing) | Jan 5 | 1 day | Sandell Scott D10% Owner | SSale | −71.4K | $2.76 | −$197.0K | −1.8%3.88M after | 2 lots |
| Jan 4, 2023 (view filing) | Dec 30, 2022-Jan 4, 2023 | 5 days | Sandell Scott D10% Owner | SSale | −398.1K | $2.98 | −$1.19M | −9.2%3.91M after | 6 lots |
| Dec 27, 2022 (view filing) | Dec 22 | 5 days | Rock EdwinChief Medical Officer | PPurchase | +110.0K | $2.25 | +$247.5K | +55.0%310.0K after | |
| Nov 18, 2022 (view filing) | Nov 17 | 1 day | Junius Daniel MDirector | PPurchase | +20.0K | $1.87 | +$37.4K | +46.2%63.3K after | |
| Nov 16, 2022 (view filing) | Nov 14-15 | 2 days | Rock EdwinChief Medical Officer | PPurchase | +200.0K | $1.55 | +$309.0K | New position200.0K after | 2 lots |
| Nov 14, 2022 (view filing) | Nov 11 | 3 days | Pearson Timothy RDirector | PPurchase | +19.4K | $1.29 | +$25.0K | +369.5%24.6K after | |
| Nov 14, 2022 (view filing) | Nov 11 | 3 days | Semerjian HaroutChief Executive Officer | PPurchase | +25.0K | $1.29 | +$32.3K | New position25.0K after | |
| Nov 14, 2022 (view filing) | Nov 11 | 3 days | Hahn Brian M.SVP Finance, CFO | PPurchase | +20.0K | $1.06 | +$21.2K | +54.3%56.8K after | |
| Nov 14, 2022 (view filing) | Nov 11 | 3 days | Magnani John L.SVP of Research, CSO | PPurchase | +45.0K | $1.17 | +$52.7K | +14.0%366.1K after | |
| Nov 14, 2022 (view filing) | Nov 11 | 3 days | Girard ArmandSVP, Chief Business Officer | PPurchase | +6.50K | $1.05 | +$6.83K | +28.7%29.2K after | |
| Mar 10, 2022 (view filing) | Mar 9 | 1 day | Magnani John L.SVP of Research, CSO | SSale | −3.23K | $1.09 | −$3.52K | −1.0%321.0K after | |
| Mar 10, 2022 (view filing) | Mar 9 | 1 day | Girard ArmandSVP, Chief Business Officer | SSale | −2.34K | $1.09 | −$2.55K | −9.4%22.7K after | |
| Mar 10, 2022 (view filing) | Mar 9 | 1 day | Hahn Brian M.SVP Finance, CFO | SSale | −2.92K | $1.09 | −$3.18K | −7.3%36.8K after | |
| Nov 18, 2021 (view filing) | Nov 16 | 2 days | Andrews Patricia SDirector | PPurchase | +40.0K | $2.05 | +$82.0K | +761.9%45.3K after |